To establish a robust clinical trial platform to support evaluation of herbal/traditional remedies, CONAT will start with therapeutics for acute respiratory viral infections including COVID-19.
We hypothesize that certain natural medicines have beneficial effects in the treatment and management of acute respiratory viral infections (ARVI) including COVID-19. When such natural medicines are well characterized in preclinical trials and or reverse pharmacology assessments, they can proceed for testing and evaluation in Phase 1B clinical trials.
- Do natural/herbal medicinal agents improve viral clearance in patients with laboratory confirmed ARVIs including COVID-19 infection?
- Do natural/herbal medicinal agents improve remission of symptoms in patients with ARVIs including COVID-19 infection?
- Do natural/herbal medicinal agents beneficially modify disease progression in patients with ARVI including COVID-19?
- Do natural/herbal medicinal agents reduce mortality in patients with ARVI including COVID-19?
The investigational medicinal products (IMPs) to be used in the trial will be herbal/natural products innovated by Ugandan scientists/herbalists for the treatment of COVID-19 and other acute respiratory infections.
The CONAT program will be accomplished through a multidisciplinary approach and collaborative efforts that bring together diverse stakeholders. The work will be accomplished through the clinical trials unit of Makerere University Lung Institute. There will be several committees including the Scientific advisory committee (SAC) and data safety monitoring board (DSMB). Day to day management will be led by Makerere University Lung Institute which is the coordinating center.